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Millions of people are living with cancer having specific mutation in p53 
gene while every single person is truly unique in genetic basis or clinical 
manifestation. The gene encodes transcription factor p53, which plays a 
central role in regulating cell cycle progression, senescence, differentiation, 
DNA repair and apoptosis in response to DNA damage or other stress 
signals. P53 activity is up regulated to initiate a cascade of biological events 
that ultimately results in prevention of tumor development. Mutations in p53 
abrogate normal tumor suppressor functions, contributing to the survival and 
proliferation of abnormal cells. Cancer cells containing mutant p53 are 
associated with more aggressive disease, increased resistance to 
chemotherapy and radiation therapy, and poor prognosis. However the 
majority of p53 mutations are missense and great number of these mutants 
represent GOF (Gain of Function) effect resulting increased invasion and 
metastasis in tumors. These mutations confer a dominant-negative activity 
over the remaining wild-type allele by functionally inactive hetero-oligomers 
interactions of the mutants with the wild-type protein. Increasing evidence 
indicates that many p53 mutants also gain new oncogenic properties that are 
independent from wild-type p53. Several factors including type of p53 
mutations in cancers may limit the efficacy and application of p53 gene 
therapy. As a result, there is a great interest in therapeutic strategies aimed at 
restoring the function of p53 for the treatment of cancer. Increasing evidence 
demonstrate that silencing GOF mutations (targeted antisense therapy) reduce 
the transactivation activity of mutant p53 and induce apoptosis in cells 
bearing these mutations then provide a potential strategy to inhibit the 
oncogenic functions of mutant p53 and improve mutant p53-targeted cancer 
therapies. 
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 The P53 protein is a nuclear phosphoprotein, 
having 393-aminoacids (5), possesses an acidic N-
terminal transactivation domain and proline-rich 
domain, with a located sequence-specific DNA-
binding domain in the center, following by an 
oligomerization domainand and a basic C-terminal 
regulatory domain (Figure1) ;this is all about the 
structure; Wild-type p53 functions as a 
homotetramer in cells (6), which play a central role 
to regulate cell cycle progression, differentiation, 
senescence, DNA repair, and apoptosis in response 
of DNA damage or other stress signals, p53 activity 
up regulate then  initiate a series of biological event 
cascade that eventually  results in prevention of 
tumor development  and expansion (7).  Recent 
studies showed, about 50% of human cancers have 
p53 mutation (8) but the frequency of it vary 
considerably between cancer types, ranging from 
~10% in hematopoietic malignancies to 50–70% in 
ovarian, colorectal and head and neck cancers (9). 
The major part of P53 mutations, observed in 
human cancers dissolve the sequence specific DNA 
binding activity about wild type p53 responsive 
elements (10). Recent studies shows greater than 
80% of the these cancer-associated p53 mutations 
are run across in the core domain, where it has six 
hot spots including Arg-175, Gly-245, Arg-248, Arg
-249, Arg-273 and Arg-282 and they perform about 
40% of all p53 mutations (11). Mutations in p53 
abrogate its normal tumor suppressor functions 
finally contributing to the survival and/or 
amplification of aberrant cells with poorly 
differentiated phenotypes, Cancer cells consist 
mutant p53 are associated more aggressive disease, 
increased resistance to radiation therapy and 
chemotherapy, with poor prognosis of the disease 
(12). Other impact Contains lack of sensitivity to 
drugs, resistance to apoptosis, increased cell 
proliferation and/or migration, enhanced 
chromosomal instability and non homologous 
recombination are characteristics of all hot spot 
mutp53 proteins, such as mutp53GOFs (11).  
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Dominant negative or Gain of Function 
mutations of TP53 gene 
The presence of p53 mutation does not necessarily 
mean the loss of p53 activity when a cell possess a 
wild-type allele together with the mutant allele. In 
this heterozygous stage, a cell containing a trans 
dominant mutant has reduced p53 activity and thus 
has a growth advantage. Moreover, p53 mutant 
cancer cells confer a dominant-negative activity 
better to say Gain of Function (GOF) activity. This 
effect arises from the fact that p53 binds DNA in the 
act of tetramer, consisting a dimer of dimers. The 
mutant and wild-type p53 proteins form hetero-
oligomers and disable to interact correct DNA target, 
on the other hand Mutant p53  inhibit wild-type p53 
inducing target gene transcription and tumour 
suppressor function (14). Increasing evidence 
showed that many p53 mutant cells also gain new 
oncogenic properties that are independent from wild-
type p53. p53 mutants that promote tumor 
progression or/and resistance to therapies become 
the most common prognostic marker for both tumor 
recurrence and death caused by cancer (9). These 
mutations reduce the ability of the wild type p53 to 
bind to its target gene responsive element. For 
example, in one study, mutant TP53 was found in 24 
of 92 (26.1%) endometrial cancers, in which 14 
cases showed dominant-negative activity that was 
associated with progressed stages, non endometrioid 
type tumors. It showed, the presence of a dominant 
negative mutant p53 was related to poor outcomes, 
suggesting that dominant negative mutant TP53 
should play a pivotal role in the progression of 
endometrial cancer (15). 
 
TP53 cancer gene therapeutic way 
On the result of many researches that p53 
inactivation is common in human cancers, it may be 
assumed that reactivation of p53 and functional 
restoration of the p53 tumor suppressor pathway is a 
potential and detrimental therapeutic way against 
cancer. Gene therapy using wild-type p53, delivered 
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Figure1: Domain structure of p53. p53 contains a natively unfolded amino-terminal transactivation domain (TAD), followed by a 
proline-rich region (PRR) with a located sequence-specific core DNA-binding domain, an oligomerization domain and C-terminal 
regulatory domain (13) 
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By adenovirus vectors, is now widespread and other 
bio-logic approaches like the development of 
oncolytic viruses designed to replicate and kill only 
p53 defective cells. The other way is the 
development of siRNA and antisense RNA's that 
activate p53 by inhibiting the function of the 
negative regulators Mdm2, MdmX, and HPV E6 is 
effective too. In conclusion Adenovirus-based p53 
gene therapy as well as using small molecules 
include PRIMA that can restore the transcriptional 
function to mutant p53 cell, or NUT-LIN and 
RITAwhich interfere with MDM2-directed p53 
degradation, have been tested in a preclinical stage 
and some of these approaches are currently in 
clinical development. 
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Conclusion 
 There is one question more needed to be answer: Cancer gene therapy on restoring p53 function:  
augmentation the wild-type p53  or silencing the mutant allele With respect to the result of all researches 
about p53, this 30 years old protein, which one is better to act or which one could have better result in the 
way of cancer gene therapy.  
